Peptide News Digest

Orforglipron ATTAIN-MAINTAIN Switch Trial, Perspective Pb-212 Radioligand Triple-Program ASCO Update, BioVaxys MVP-S Survivin Vaccine, BriaCell $4.7M Offering, Venom-Peptide AI Platform

Orforglipron maintains weight loss after switching off injectables, Perspective's lead-212 radioligands and BioVaxys' survivin vaccine reach ASCO, BriaCell raises $4.7M.

6 stories · Covering clinical-trials, research, industry

Editor's Note

ASCO's Sunday sits between EASL's Saturday close and the meeting's heaviest peptide-oncology day on Monday, June 1, when Bicycle's Duravelo-2, Mayo's TPIV200 folate-receptor vaccine, and Telix's ProstACT reach the podium. The targeting modality keeps widening: Perspective pairs a somatostatin-targeting peptide with a lead-212 alpha emitter across three tumor types, while BioVaxys' MVP-S strings five survivin-derived peptides into a single cancer vaccine. On the metabolic side, the news has moved past how much weight a drug takes off to whether patients can hold the loss, which is what Lilly's ATTAIN-MAINTAIN switch trial set out to test. BriaCell's small registered-direct raise shows how micro-cap immuno-oncology names convert conference data into working capital. Discovery platforms feed the far end of the pipeline, with venom-derived scaffolds and machine learning generating binders against targets that resisted conventional approaches.

Clinical Trials

Lilly Orforglipron ATTAIN-MAINTAIN Phase 3b: Patients Switching Off Injectable Semaglutide or Tirzepatide to the Oral Pill Held 75-80% of Their Weight Loss Over 52 Weeks

Published May 12 in Nature Medicine and presented at ECO 2026, the first-of-its-kind ATTAIN-MAINTAIN trial (NCT06584916) tested whether adults who had already lost substantial weight on Wegovy or Zepbound could maintain it after switching to once-daily orforglipron. Over 52 weeks, the semaglutide-switch group regained an average of 1 kg and the tirzepatide-switch group an average of 5 kg, with most cardiometabolic gains preserved. Carel le Roux and Louis Aronne led the analysis.

#orforglipron #foundayo #eli-lilly #attain-maintain #oral-glp-1 #weight-maintenance #eco-2026
Clinical Trials

Perspective Therapeutics Brings Lead-212 Alpha-Radioligand Platform to ASCO 2026 With Updates Across VMT-α-NET, VMT01, and PSV359

Perspective Therapeutics presented progress on its three clinical lead-212 (²¹²Pb) targeted alpha-therapy programs at ASCO 2026: [212Pb]VMT-α-NET in somatostatin-receptor-2-positive neuroendocrine tumors, VMT01 in melanoma, and PSV359 in solid tumors. The NET program's earlier Phase 1/2a readout showed a 39% objective response rate in its second cohort and no dose-limiting toxicities at the 5.0 mCi dose, supporting movement toward a registrational trial. The platform pairs a peptide-based targeting vector with a short-range alpha emitter.

#perspective-therapeutics #vmt-alpha-net #lead-212 #radioligand #neuroendocrine-tumors #sstr2 #asco-2026 #alpha-emitter
Clinical Trials

BioVaxys MVP-S Survivin Peptide Vaccine Reaches ASCO 2026 With Positive PESCO Phase 1b/2 Data in Recurrent Ovarian Cancer

BioVaxys presented results from the investigator-initiated PESCO trial of maveropepimut-S (MVP-S) combined with pembrolizumab and low-dose cyclophosphamide in recurrent epithelial ovarian cancer. MVP-S is a DPX-based vaccine built from five survivin-derived peptides plus a T-helper peptide and an innate immune stimulant, designed to drive a cytotoxic T-cell response against survivin, an antigen highly expressed in ovarian tumors but nearly absent in normal tissue.

#biovaxys #mvp-s #maveropepimut-s #survivin #peptide-vaccine #ovarian-cancer #dpx-platform #asco-2026
Research

Machine-Learning Venom-Peptide Platform Builds 482-Scaffold Library and Hits All Four Test Targets

A venom-peptide discovery system published in Pharmaceuticals (MDPI) in 2026 paired phage display with a machine-learning model that predicts mutation-tolerant residues, building a library from roughly 482 venom-derived scaffolds. Screened against CD47, DLL3, IL33, and P2X7R, the resulting VCX library yielded strong binders for all four targets. Venom peptides are stabilized by multiple disulfide bonds and naturally evolved to hit GPCRs and ion channels, giving them structural stability that conventional peptides often lack.

#venom-peptides #phage-display #machine-learning #peptide-discovery #disulfide-bonds #cd47 #dll3 #ai-drug-design
Industry

BriaCell Prices $4.7M Registered Direct Offering at $3.25 a Share Following ASCO 2026 Bria-IMT Data

BriaCell Therapeutics priced a registered direct offering of 1,449,300 common shares at $3.25 each for gross proceeds of about $4.7 million, with ThinkEquity as sole placement agent. The company plans to use proceeds for working capital, general corporate purposes, and advancing its pipeline. The raise lands days after BriaCell reported 16.6-month median overall survival for its Bria-IMT cell-based immunotherapy in heavily pretreated metastatic breast cancer at ASCO 2026.

#briacell #registered-direct-offering #thinkequity #bria-imt #financing #metastatic-breast-cancer #asco-2026
Industry

ASCO 2026 Day 3 (Sunday, May 31) — Peptide and Conjugate Oncology Slate Builds Toward Monday's June 1 Podium Block

ASCO's Sunday education and poster sessions in Chicago set up the meeting's densest peptide-oncology day on Monday, June 1, when Bicycle Therapeutics presents Duravelo-2 (zelenectide pevedotin in first-line urothelial cancer, Abstract 4516), Mayo Clinic presents the TPIV200 folate-receptor-alpha vaccine in triple-negative breast cancer (Abstract 536), and Telix presents ProstACT Global PSMA radioligand data. Corbus CRB-701 and BioVaxys MVP-S round out the targeted-conjugate and vaccine slate.

#asco-2026 #peptide-oncology #day-3 #bicycle-therapeutics #mayo-clinic #telix-pharmaceuticals #chicago